Researchers of this new study found that treatment with venetoclax may be able to restore activation and proliferation of these cells, suggesting their plasticity can be leveraged for autologous ...

T cell surface markers CD4 and LAG-3 are related proteins that promote and inhibit cell activity, respectively. However, although LAG-3 has started to gain appreciation as an immune checkpoint ...

A study led by researchers at the University of Arizona Health Sciences discovered new information about the inner workings of the immune system that could have a profound impact on T cell therapies ...

A new review summarizes how CD4+ cytotoxic T cells act as both protective and pathological effectors, and why targeting them therapeutically remains difficult.

Cancer immunotherapy using "designer" immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient's ...

Researchers found that CD4+ T cells can be classified into 18 categories and 12 distinct gene programs, and that characteristic changes in CD4+ T cell profiles are associated with autoimmune disease, ...

CD4 counts show how strong your immune system is; lower counts mean a weaker immune response. The CD4 percentage shows what part of your white blood cells are CD4 cells and helps check how strong your ...

When T cells are activated, they upregulate glycolysis and take on a requisite Warburg phenotype. In this study, we evaluated the effect of inhibiting two distinct glycolytic enzymes, GAPDH and PGAM, ...

Conservation of their respective cytoplasmic tail motifs, CxC/H in the case of CD4 and an ITIM-like motif in the case of LAG-3, supports that competition between CD4 and LAG-3 for binding of kinase ...